IP Library › Patent Application 17114383
Patent Application
App. No. 17/114,383

HYALURONIC ACID-BINDING SYNTHETIC PEPTIDOGLYCANS, PREPARATION, AND METHODS OF USE

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
17/114,383
Abstract

This invention pertains to the field of hyaluronic acid-binding synthetic peptidoglycans and methods of forming and using the same.

Claims (237)

1 . A synthetic peptidoglycan comprising a synthetic peptide covalently conjugated to a glycan wherein the synthetic peptide comprises a hyaluronic acid-binding sequence.

2 . The synthetic peptidoglycan of claim 1 wherein the synthetic peptide comprises an amino acid sequence of the formula B1-X1-X2-X3-X4-X5-X6-X7-X8-B2,

wherein X8 is present or is not present,

wherein B1 is a basic amino acid,

wherein B2 is a basic amino acid, and

wherein X1-X8 are non-acidic amino acids.

3 . The synthetic peptidoglycan of claim 1 wherein the synthetic peptide comprises an amino acid sequence selected from the group consisting of:

(SEQ ID NO: 2)

GAHWQFNALTVRGG;

(SEQ ID NO: 3)

GDRRRRRMWHRQ;

(SEQ ID NO: 4)

GKHLGGKHRRSR;

(SEQ ID NO: 5)

RGTHHAQKRRS;

(SEQ ID NO: 6)

RRHKSGHIQGSK;

(SEQ ID NO: 7)

SRMHGRVRGRHE;

(SEQ ID NO: 8)

RRRAGLTAGRPR;

(SEQ ID NO: 9)

RYGGHRTSRKWV;

(SEQ ID NO: 10)

RSARYGHRRGVG;

(SEQ ID NO: 11)

GLRGNRRVFARP;

(SEQ ID NO: 12)

SRGQRGRLGKTR;

(SEQ ID NO: 13)

DRRGRSSLPKLAGPVEFPDRKIKGRR;

(SEQ ID NO: 14)

RMRRKGRVKHWG;

(SEQ ID NO: 15)

RGGARGRHKTGR;

(SEQ ID NO: 16)

TGARQRGLQGGWGPRHLRGKDQPPGR;

(SEQ ID NO: 17)

RQRRRDLTRVEG;

(SEQ ID NO: 18)

STKDHNRGRRNVGPVSRSTLRDPIRR;

(SEQ ID NO: 19)

RRIGHQVGGRRN;

(SEQ ID NO: 20)

RLESRAAGQRRA;

(SEQ ID NO: 21)

GGPRRHLGRRGH;

(SEQ ID NO: 22)

VSKRGHRRTAHE;

(SEQ ID NO: 23)

RGTRSGSTR;

(SEQ ID NO: 24)

RRRKKIQGRSKR;

(SEQ ID NO: 25)

RKSYGKYQGR;

(SEQ ID NO: 26)

KNGRYSISR;

(SEQ ID NO: 27)

RRRCGQKKK;

(SEQ ID NO: 28)

KQKIKHVVKLK;

(SEQ ID NO: 29)

KLKSQLVKRK;

(SEQ ID NO: 30)

RYPISRPRKR;

(SEQ ID NO: 31)

KVGKSPPVR;

(SEQ ID NO: 32)

KTFGKMKPR;

(SEQ ID NO: 33)

RIKWSRVSK;

and

(SEQ ID NO: 34)

KRTMRPTRR.

4 . The synthetic peptidoglycan of claim 1 wherein the glycan is selected from the group consisting of dextran, chondroitin, chondroitin sulfate, dermatan, dermatan sulfate, heparan, heparin, keratin, keratan sulfate, and hyaluronic acid.

5 . The synthetic peptidoglycan of claim 1 wherein the synthetic peptidoglycan is resistant to aggrecanase.

6 . The synthetic peptidoglycan of claim 1 wherein the peptide component of the synthetic peptidoglycan has a glycine-cysteine attached to the C-terminus of the peptide.

7 . An engineered collagen matrix comprising polymerized collagen, hyaluronic acid, and a hyaluronic acid-binding synthetic peptidoglycan comprising a peptide component and a glycan component.

8 . The engineered collagen matrix of claim 7 wherein the peptide component of the synthetic peptidoglycan comprises an amino acid sequence of the formula B1-X1-X2-X3-X4-X5-X6-X7-X8-B2,

wherein X8 is present or is not present,

wherein B1 is a basic amino acid,

wherein B2 is a basic amino acid, and

wherein X1-X8 are non-acidic amino acids.

9 . The engineered collagen matrix of claim 7 wherein the peptide component of the synthetic peptidoglycan comprises an amino acid sequence selected from the group consisting of:

(SEQ ID NO: 2)

GAHWQFNALTVRGG;

(SEQ ID NO: 3)

GDRRRRRMWHRQ;

(SEQ ID NO: 4)

GKHLGGKHRRSR;

(SEQ ID NO: 5)

RGTHHAQKRRS;

(SEQ ID NO: 6)

RRHKSGHIQGSK;

(SEQ ID NO: 7)

SRMHGRVRGRHE;

(SEQ ID NO: 8)

RRRAGLTAGRPR;

(SEQ ID NO: 9)

RYGGHRTSRKWV;

(SEQ ID NO: 10)

RSARYGHRRGVG;

(SEQ ID NO: 11)

GLRGNRRVFARP;

(SEQ ID NO: 12)

SRGQRGRLGKTR;

(SEQ ID NO: 13)

DRRGRSSLPKLAGPVEFPDRKIKGRR;

(SEQ ID NO: 14)

RMRRKGRVKHWG;

(SEQ ID NO: 15)

RGGARGRHKTGR;

(SEQ ID NO: 16)

TGARQRGLQGGWGPRHLRGKDQPPGR;

(SEQ ID NO: 17)

RQRRRDLTRVEG;

(SEQ ID NO: 18)

STKDHNRGRRNVGPVSRSTLRDPIRR;

(SEQ ID NO: 19)

RRIGHQVGGRRN;

(SEQ ID NO: 20)

RLESRAAGQRRA;

(SEQ ID NO: 21)

GGPRRHLGRRGH;

(SEQ ID NO: 22)

VSKRGHRRTAHE;

(SEQ ID NO: 23)

RGTRSGSTR;

(SEQ ID NO: 24)

RRRKKIQGRSKR;

(SEQ ID NO: 25)

RKSYGKYQGR;

(SEQ ID NO: 26)

KNGRYSISR;

(SEQ ID NO: 27)

RRRCGQKKK;

(SEQ ID NO: 28)

KQKIKHVVKLK;

(SEQ ID NO: 29)

KLKSQLVKRK;

(SEQ ID NO: 30)

RYPISRPRKR;

(SEQ ID NO: 31)

KVGKSPPVR;

(SEQ ID NO: 32)

KTFGKMKPR;

(SEQ ID NO: 33)

RIKWSRVSK;

and

(SEQ ID NO: 34)

KRTMRPTRR.

10 . The engineered collagen matrix of claim 7 wherein the glycan component of the synthetic peptidoglycan is selected from the group consisting of dextran, chondroitin, chondroitin sulfate, dermatan, dermatan sulfate, heparan, heparin, keratin, keratan sulfate, and hyaluronic acid.

11 . The engineered collagen matrix of claim 7 wherein the synthetic peptidoglycan is resistant to aggrecanase.

12 . The engineered collagen matrix of claim 7 wherein the peptide component of the synthetic peptidoglycan has a glycine-cysteine attached to the C-terminus of the peptide.

13 . The engineered collagen matrix of claim 7 wherein the matrix further comprises an exogenous population of cells.

14 . A method of treatment for arthritis in a patient, said method comprising the step of administering to the patient a hyaluronic acid-binding synthetic peptidoglycan comprising a peptide component and a glycan component, wherein the synthetic peptidoglycan reduces a symptom associated with the arthritis.

15 . The method of claim 14 wherein the peptide component of the synthetic peptidoglycan comprises an amino acid sequence of the formula B1-X1-X2-X3-X4-X5-X6-X7-X8-B2,

wherein X8 is present or is not present,

wherein B1 is a basic amino acid,

wherein B2 is a basic amino acid, and

wherein X1-X8 are non-acidic amino acids.

16 . The method of claim 14 wherein the peptide component of the synthetic peptidoglycan comprises an amino acid sequence selected from the group consisting of:

(SEQ ID NO: 2)

GAHWQFNALTVRGG;

(SEQ ID NO: 3)

GDRRRRRMWHRQ;

(SEQ ID NO: 4)

GKHLGGKHRRSR;

(SEQ ID NO: 5)

RGTHHAQKRRS;

(SEQ ID NO: 6)

RRHKSGHIQGSK;

(SEQ ID NO: 7)

SRMHGRVRGRHE;

(SEQ ID NO: 8)

RRRAGLTAGRPR;

(SEQ ID NO: 9)

RYGGHRTSRKWV;

(SEQ ID NO: 10)

RSARYGHRRGVG;

(SEQ ID NO: 11)

GLRGNRRVFARP;

(SEQ ID NO: 12)

SRGQRGRLGKTR;

(SEQ ID NO: 13)

DRRGRSSLPKLAGPVEFPDRKIKGRR;

(SEQ ID NO: 14)

RMRRKGRVKHWG;

(SEQ ID NO: 15)

RGGARGRHKTGR;

(SEQ ID NO: 16)

TGARQRGLQGGWGPRHLRGKDQPPGR;

(SEQ ID NO: 17)

RQRRRDLTRVEG;

(SEQ ID NO: 18)

STKDHNRGRRNVGPVSRSTLRDPIRR;

(SEQ ID NO: 19)

RRIGHQVGGRRN;

(SEQ ID NO: 20)

RLESRAAGQRRA;

(SEQ ID NO: 21)

GGPRRHLGRRGH;

(SEQ ID NO: 22)

VSKRGHRRTAHE;

(SEQ ID NO: 23)

RGTRSGSTR;

(SEQ ID NO: 24)

RRRKKIQGRSKR;

(SEQ ID NO: 25)

RKSYGKYQGR;

(SEQ ID NO: 26)

KNGRYSISR;

(SEQ ID NO: 27)

RRRCGQKKK;

(SEQ ID NO: 28)

KQKIKHVVKLK;

(SEQ ID NO: 29)

KLKSQLVKRK;

(SEQ ID NO: 30)

RYPISRPRKR;

(SEQ ID NO: 31)

KVGKSPPVR;

(SEQ ID NO: 32)

KTFGKMKPR;

(SEQ ID NO: 33)

RIKWSRVSK; 

and

(SEQ ID NO: 34)

KRTMRPTRR.

17 . The method of claim 14 wherein the glycan component of the synthetic peptidoglycan is selected from the group consisting of dextran, chondroitin, chondroitin sulfate, dermatan, dermatan sulfate, heparan, heparin, keratin, keratan sulfate, and hyaluronic acid.

18 . The method of claim 14 wherein the synthetic peptidoglycan is resistant to aggrecanase.

19 . The method of claim 14 wherein the peptide component of the synthetic peptidoglycan has a glycine-cysteine attached to the C-terminus of the peptide.

20 . The method of claim 14 wherein the arthritis is selected from the group consisting of osteoarthritis and rheumatoid arthritis.

21 . The method of claim 14 wherein the dosage of the synthetic peptidoglycan is in a concentration ranging from about 0.1 μM to about 10 μM.

22 . The synthetic peptidoglycan of claim 1 wherein the synthetic peptidoglycan is resistant to matrix metallo proteases.

23 . The engineered collagen matrix of claim 7 wherein the synthetic peptidoglycan is resistant to matrix metallo proteases.

24 . The method of claim 14 wherein the synthetic peptidoglycan is resistant to matrix metallo proteases.